BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.65 --0%
Revenue Growth %: +13.7%
Financial Fact:
Product sales: 0
Today's EPS Names:
PKE, LNN, More
Revenue Growth %: +13.7%
Financial Fact:
Product sales: 0
Today's EPS Names:
PKE, LNN, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), versus ($0.34) reported last year. Revenue for the quarter came in at $47.2 million, versus $4 million reported last year.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
- Burberry Group PLC (BRBY:LN) (BBRYF) PT Raised to GBP14.25 at UBS
- Emkay Global Starts Vedanta Aluminium Metal (VAML:IN) at Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
